Opioid Taper Request in a Patient on Chronic Therapy
A 61-year-old woman with chronic low back pain has been on oxycodone 10 mg every 6 hours (40 mg morphine milligram equivalents per day) for four years, prescribed by a departing physician. She also takes alprazolam 0.5 mg three times daily for anxiety and gabapentin 300 mg three times daily. She requests an early refill two weeks into a 30-day supply, saying her pain is worse after a fall. The state prescription database shows she filled a 7-day supply of oxycodone from an urgent care eight days ago and did not disclose it. She denies using more than prescribed. Vitals are stable; she appears uncomfortable but not sedated. She has no history of overdose and no documented opioid use disorder.
1. How should the clinician respond to the early refill request and the database discrepancy?
Read the worked answer
Address the discrepancy directly but nonjudgmentally. The database shows an undisclosed 7-day oxycodone fill from urgent care eight days ago, which means she may have overlapping supplies and a higher actual intake than the prescribed 40 MME/day. Ask open-ended questions about what happened at urgent care, how much she is actually taking, and whether she is running out early or accumulating. Reconcile all sources: the departing prescriber's records, the urgent care note, and pharmacy fill history. Do not simply refill or abruptly refuse; both are unsafe. If she is genuinely out and at risk of withdrawal or uncontrolled pain, provide a limited bridge supply with a clear plan, while setting expectations about a single prescriber and single pharmacy. Screen for opioid use disorder using a validated tool, and assess for sedation, respiratory risk, and concurrent benzodiazepine use. Document the conversation and the plan.
2. What are the key safety concerns with her current regimen, and how should they be addressed?
Read the worked answer
The combination of oxycodone, alprazolam, and gabapentin substantially raises the risk of sedation and respiratory depression, especially if her opioid intake has increased. The benzodiazepine-opioid combination carries a boxed warning. Her fall is a red flag for both injury and medication-related impairment. Steps: calculate and document total MME including all sources; review the PDMP at every visit; assess sedation with a validated scale and ask about snoring or witnessed apnea; consider whether the alprazolam can be cautiously tapered in coordination with her mental health prescriber, since abrupt discontinuation is dangerous. Do not stop her medications abruptly. Offer naloxone and educate her and a household member on use. Consider a urine drug screen with her consent. Reassess whether gabapentin is contributing to sedation. Evaluate the fall for injury and review fall risk factors. Set clear boundaries: one prescriber, one pharmacy, no early refills without contact, and pill counts if indicated.
3. What treatment plan balances pain control, safety, and regulatory obligations?
Read the worked answer
Build a written plan: continue a stable opioid dose at the lowest effective level, with a defined bridge if she is truly out, and require PDMP review at each visit. Add non-opioid modalities: physical therapy, topical agents, and a structured exercise plan; review whether gabapentin is optimized for neuropathic features. Coordinate with her mental health prescriber on the alprazolam, aiming for gradual reduction rather than abrupt stop. Provide naloxone and document the offer. Establish a controlled substance agreement covering single prescriber, single pharmacy, early refill policy, and random monitoring. Refer for substance use evaluation if screening suggests opioid use disorder; if criteria are met, offer buprenorphine or other treatment rather than discharge. Document medical decision-making, the risk-benefit discussion, and the rationale for continuing therapy. Follow state prescribing rules, including PDMP check requirements and any limits. Schedule a short-interval follow-up (2-4 weeks) to reassess function and safety.